Successful induction of protective antibody responses against Haemophilus influenzae type b and diphtheria after transcutaneous immunization with the glycoconjugate polyribosyl ribitol phosphate-cross-reacting material 197 vaccine.
We examined the antibody responses elicited in rats after transcutaneous immunization (TCI) with the Haemophilus influenzae type b (Hib)-cross-reacting material (CRM(197)) glycoconjugate vaccine coadministered with cholera toxin or mutants of heat-labile enterotoxin of Escherichia coli (LTK63 and LTR72) as adjuvants. The glycoconjugate vaccine was immunogenic, eliciting high antibody responses to the capsular polysaccharide of Hib and to diphtheria toxin. Passively transferred immune serum protected infant rats against challenge with the Hib Eagan strain and exhibited strong neutralizing activity against diphtheria toxin both in vitro and in vivo. The finding that TCI of rats can elicit antibody responses surpassing the minimum levels required for protective immunity against Hib and diphtheria suggests that this immunization strategy holds a lot of promise for future pediatric use. However, further studies are required to confirm the potential of TCI with glycoconjugate vaccines in humans.
Mawas
Fatme
F
Division of Bacteriology, National Institute for Biological Standards and Control, Hertfordshire, United Kingdom.
Peyre
Marisa
M
Beignon
Anne-Sophie
AS
Frost
Laura
L
Del Giudice
Giuseppe
G
Rappuoli
Rino
R
Muller
Sylviane
S
Sesardic
Dorothea
D
Partidos
Charalambos D
CD
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000279:Administration, Cutaneous; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis* / Q000097:blood / Q000276:immunology; D016667:Bacterial Capsules; D001426:Bacterial Proteins / Q000008:administration & dosage* / Q000276:immunology; D001427:Bacterial Toxins / Q000008:administration & dosage / Q000276:immunology; D002772:Cholera Toxin / Q000008:administration & dosage / Q000276:immunology; D004167:Diphtheria Toxin / Q000276:immunology*; D004768:Enterotoxins / Q000008:administration & dosage / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D029968:Escherichia coli Proteins; D005260:Female; D006001:Glycoconjugates / Q000276:immunology; D006192:Haemophilus Infections / Q000276:immunology* / Q000517:prevention & control; D018073:Haemophilus Vaccines / Q000008:administration & dosage* / Q000276:immunology; D019741:Haemophilus influenzae type b / Q000276:immunology*; D007116:Immunization, Passive; D011134:Polysaccharides / Q000276:immunology; D011135:Polysaccharides, Bacterial / Q000276:immunology; D051381:Rats; D017207:Rats, Sprague-Dawley; D014611:Vaccination; D018074:Vaccines, Conjugate / Q000276:immunology
D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; D001427:Bacterial Toxins; D004167:Diphtheria Toxin; D004768:Enterotoxins; D029968:Escherichia coli Proteins; D006001:Glycoconjugates; D018073:Haemophilus Vaccines; C044237:Haemophilus influenzae type b polysaccharide vaccine; D011134:Polysaccharides; D011135:Polysaccharides, Bacterial; D018074:Vaccines, Conjugate; C028581:CRM197 (non-toxic variant of diphtheria toxin); C061963:HibTITER protein, Haemophilus influenzae; C008984:polyribitol phosphate; D002772:Cholera Toxin; C027538:heat-labile enterotoxin, E coli